Arcutis Biotherapeutics, Inc. (ARQT) Market Cap & Valuation Ratios
Arcutis Biotherapeutics, Inc. (ARQT) has a market cap of $3.9B, a trailing P/E of 148.6 and a price-to-sales ratio of 8.4, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ARQTArcutis Biotherapeutics, Inc.Follow ARQT — free
—
Price chart with a free account
- Market cap
- 3.9B
- P/E TTM
- 148.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| ARQT | 3.9 | 148.6 | 8.2 | 103.9 | 1.0% | +76% | 7% | 14% |
| CRSP | 4.8 | — | 223.8 | — | -7.8% | -65% | — | -30% |
| TVTX | 4.7 | — | 8.5 | 219.5 | 2.0% | +77% | -7% | -8% |
| GOSS | 4.6 | — | 86.3 | — | -3.5% | +32% | -312% | — |
| DNTH | 4.3 | — | — | — | -3.6% | -61% | — | -32% |
| EWTX | 4.3 | — | — | — | -3.7% | — | — | -48% |
| RLAY | 4.0 | — | 373.2 | — | -5.3% | +24% | — | -47% |
| TNGX | 3.9 | — | 54.3 | — | -3.7% | +121% | -253% | -35% |
| XENE | 3.4 | — | — | — | -9.9% | — | — | -54% |
| ACAD | 3.4 | 8.8 | 2.1 | 25.1 | 4.3% | +12% | 8% | 9% |
| IDYA | 3.3 | — | 10.8 | — | -3.4% | +3024% | -93% | -24% |
| Median of these 10 | 8.8 | 54.3 | 122.3 | -3.6% | +28% | -93% | -32% |
P/E 148.6 vs. a peer median of 8.8; EV/Sales 8.2 vs. 54.3.
Growth vs. price
each dot a company · hover or tap for valuesArcutis Biotherapeutics, Inc. — questions
- What is Arcutis Biotherapeutics, Inc.'s market cap?
- $3.9B.
- What is Arcutis Biotherapeutics, Inc.'s P/E ratio?
- 148.6 on trailing twelve-month earnings to 2026-06-30.
- What is Arcutis Biotherapeutics, Inc.'s price-to-sales ratio?
- 8.4.
Every figure on this page comes from Arcutis Biotherapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.